The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope

Louise Mercer; Abhishek Abhishek; Akhila Kavirayani; Alison Ahmed; Alan Davidson; Amy Foulkes; Claire Jones; Clare Nash; Emily Rose-Parfitt; Emmandeep Dhillon; Genevieve Zabate; Helen Twohig; Hope De Vere; Jennifer Scott; John Reynolds; Julia Holmes; Karen Hartley; Kishore Warrier; Kataryzna Nowak; Kate Parsons; Katie Bechman; Lisa Bray; Madura Adikari; Natasha Wood; Nicola Faithfull; Nicola Gullick; Pratyasha Saha; Rebecca Heaton; Samundeeswari Deepak; Samantha Hider; Sameena Khalid; Sanaa Suleiman Said; Sarah Ryan; Stuart Kyle; Subhra Raghuvanshi; Su-Yin Tan; Vinay Shivamurthy; James Galloway

doi:10.1093/rap/rkae077

The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope

Louise Mercer^*, Abhishek Abhishek, Akhila Kavirayani, Alison Ahmed, Alan Davidson, Amy Foulkes, Claire Jones, Clare Nash, Emily Rose-Parfitt, Emmandeep Dhillon, Genevieve Zabate, Helen Twohig, Hope De Vere, Jennifer Scott, John Reynolds, Julia Holmes, Karen Hartley, Kishore Warrier, Kataryzna Nowak, Kate ParsonsKatie Bechman, Lisa Bray, Madura Adikari, Natasha Wood, Nicola Faithfull, Nicola Gullick, Pratyasha Saha, Rebecca Heaton, Samundeeswari Deepak, Samantha Hider, Sameena Khalid, Sanaa Suleiman Said, Sarah Ryan, Stuart Kyle, Subhra Raghuvanshi, Su-Yin Tan, Vinay Shivamurthy, James Galloway

^*Corresponding author for this work

Inflammation and Ageing

Research output: Contribution to journal › Review article › peer-review

68 Downloads (Pure)

Abstract

This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology’s ‘Creating clinical guidelines: our protocol’, updated 2023.

Original language	English
Article number	rkae077
Number of pages	5
Journal	Rheumatology Advances in Practice
Volume	8
Issue number	3
Early online date	12 Jul 2024
DOIs	https://doi.org/10.1093/rap/rkae077
Publication status	E-pub ahead of print - 12 Jul 2024

Keywords

DMARD management guideline

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/rap/rkae077Licence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

MercerL2024prescription Final published version, 504 KBLicence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

Cite this

Mercer, L., Abhishek, A., Kavirayani, A., Ahmed, A., Davidson, A., Foulkes, A., Jones, C., Nash, C., Rose-Parfitt, E., Dhillon, E., Zabate, G., Twohig, H., De Vere, H., Scott, J., Reynolds, J., Holmes, J., Hartley, K., Warrier, K., Nowak, K., ... Galloway, J. (2024). The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope. Rheumatology Advances in Practice, 8(3), Article rkae077. Advance online publication. https://doi.org/10.1093/rap/rkae077

@article{7a97ec4a2f09431fbdefdd8beca6e596,

title = "The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope",

abstract = "This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology{\textquoteright}s {\textquoteleft}Creating clinical guidelines: our protocol{\textquoteright}, updated 2023.",

keywords = "DMARD management guideline",

author = "Louise Mercer and Abhishek Abhishek and Akhila Kavirayani and Alison Ahmed and Alan Davidson and Amy Foulkes and Claire Jones and Clare Nash and Emily Rose-Parfitt and Emmandeep Dhillon and Genevieve Zabate and Helen Twohig and {De Vere}, Hope and Jennifer Scott and John Reynolds and Julia Holmes and Karen Hartley and Kishore Warrier and Kataryzna Nowak and Kate Parsons and Katie Bechman and Lisa Bray and Madura Adikari and Natasha Wood and Nicola Faithfull and Nicola Gullick and Pratyasha Saha and Rebecca Heaton and Samundeeswari Deepak and Samantha Hider and Sameena Khalid and Said, {Sanaa Suleiman} and Sarah Ryan and Stuart Kyle and Subhra Raghuvanshi and Su-Yin Tan and Vinay Shivamurthy and James Galloway",

year = "2024",

month = jul,

day = "12",

doi = "10.1093/rap/rkae077",

language = "English",

volume = "8",

journal = "Rheumatology Advances in Practice",

issn = "2514-1775",

publisher = "Oxford University Press",

number = "3",

}

Mercer, L, Abhishek, A, Kavirayani, A, Ahmed, A, Davidson, A, Foulkes, A, Jones, C, Nash, C, Rose-Parfitt, E, Dhillon, E, Zabate, G, Twohig, H, De Vere, H, Scott, J, Reynolds, J, Holmes, J, Hartley, K, Warrier, K, Nowak, K, Parsons, K, Bechman, K, Bray, L, Adikari, M, Wood, N, Faithfull, N, Gullick, N, Saha, P, Heaton, R, Deepak, S, Hider, S, Khalid, S, Said, SS, Ryan, S, Kyle, S, Raghuvanshi, S, Tan, S-Y, Shivamurthy, V & Galloway, J 2024, 'The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope', Rheumatology Advances in Practice, vol. 8, no. 3, rkae077. https://doi.org/10.1093/rap/rkae077

TY - JOUR

T1 - The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs

T2 - British Society for Rheumatology guideline scope

AU - Mercer, Louise

AU - Abhishek, Abhishek

AU - Kavirayani, Akhila

AU - Ahmed, Alison

AU - Davidson, Alan

AU - Foulkes, Amy

AU - Jones, Claire

AU - Nash, Clare

AU - Rose-Parfitt, Emily

AU - Dhillon, Emmandeep

AU - Zabate, Genevieve

AU - Twohig, Helen

AU - De Vere, Hope

AU - Scott, Jennifer

AU - Reynolds, John

AU - Holmes, Julia

AU - Hartley, Karen

AU - Warrier, Kishore

AU - Nowak, Kataryzna

AU - Parsons, Kate

AU - Bechman, Katie

AU - Bray, Lisa

AU - Adikari, Madura

AU - Wood, Natasha

AU - Faithfull, Nicola

AU - Gullick, Nicola

AU - Saha, Pratyasha

AU - Heaton, Rebecca

AU - Deepak, Samundeeswari

AU - Hider, Samantha

AU - Khalid, Sameena

AU - Said, Sanaa Suleiman

AU - Ryan, Sarah

AU - Kyle, Stuart

AU - Raghuvanshi, Subhra

AU - Tan, Su-Yin

AU - Shivamurthy, Vinay

AU - Galloway, James

PY - 2024/7/12

Y1 - 2024/7/12

N2 - This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology’s ‘Creating clinical guidelines: our protocol’, updated 2023.

AB - This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology’s ‘Creating clinical guidelines: our protocol’, updated 2023.

KW - DMARD management guideline

U2 - 10.1093/rap/rkae077

DO - 10.1093/rap/rkae077

M3 - Review article

SN - 2514-1775

VL - 8

JO - Rheumatology Advances in Practice

JF - Rheumatology Advances in Practice

IS - 3

M1 - rkae077

ER -

The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this